-+ 0.00%
-+ 0.00%
-+ 0.00%

NEXGEL Announces Consideration Terms Of Agreement To License And Acquire Portfolio Of Commercial-Stage Regenerative Biomaterial Products From Celularity; Consideration To Include $15M Upfront Cash Payment And Addl. $20M In Milestone Payments

Benzinga·03/12/2026 12:53:34
Listen to the news

Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing

LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the consideration terms of its previously announced agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc. ("Celularity") (NASDAQ:CELU), a regenerative and cellular medicine company.

Consideration for the portfolio will include a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on various annual net sales targets related to the portfolio.

The transaction represents the most significant milestone in the Company's history and is expected to approximately triple NEXGEL's revenue base and expected to make the Company profitable immediately upon closing.

The existing portfolio of 6 products encompasses a diversified suite of established regenerative biomaterial products and technologies focused on tendon repair, skin grafts, and bone growth—all within the rapidly growing regenerative biomaterials market. These products carry over a decade of clinical use, demonstrated clinical utility, and existing insurance reimbursement pathways. Critically, the transaction is expected to bring an experienced commercial and scientific team to NEXGEL, meaningfully expanding the Company's capabilities and reach in the medical technology sector.

The transaction is subject to customary closing processes and financing. A Current Report on Form 8-K containing further details regarding the contemplated transaction was be filed by NEXGEL on March 10, 2026 and is available on the U.S. Securities and Exchange Commission's EDGAR website.